Discoveries into brain tumour at QBI, using generous funds from our donors, will continue to progress at UQ, translating knowledge into possible treatments.

Key advances in our understanding of the development of the most common type of malignant brain tumour among adults, glioblastoma, have been carried out at QBI and recognised internationally in the cancer field.

Our important discovery that nuclear factor one (NF1) genes control how cancer cells change in glioblastoma has propelled research into therapies targeting the NF1 pathway.

Our researchers demonstrated, in mice with glioblastoma, that NF1 stopped cancer cells growing and transformed them back into more normal brain cells.

These significant findings into how brain cancer develops will continue to advance by being translated into therapeutics at UQ’s Centre for Advanced Imaging (CAI) and Australian Institute for Bioengineering and Nanotechnology (AIBN).

The work will be led by long-time QBI collaborators Dr Zachery Houston and Associate Professor Kristofer J. Thurecht, who are world leaders in developing nanomedicines.

Researchers Dr Jens Bunt and Dr Kok-Siong Chen, whose tireless work contributed to these discoveries, have taken up positions at the Princess Maxima Centre for Paediatric Oncology in the Netherlands and the Centre for Stem Cell Therapeutics and Imaging at Harvard Medical School, respectively. Their important work has created a legacy at QBI and UQ for extending this valuable fundamental knowledge from the laboratory bench to the bedside.

To continue to support this pioneering brain tumour research at UQ, we welcome donations to the Australian Institute for Bioengineering and Nanotechnology (AIBN).

 

  What is brain cancer?

  Types of brain cancer

  Signs and symptoms of brain cancer

  Diagnosing and treating brain cancer